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Abstract
Clostridium difficile (C. difficile) infection is a leading cause of morbidity and mortality
in the United States, making the infection a top public health priority. Early and accurate
identification of disease is a critical factor in successful management, including clinical
symptomology. The testing methods for C. difficile have improved in efficiency and
sensitivity, which potentially causes over- or underprescribing behavior. Guided by the
symbolic theory, the purpose of this study was to examine the association between C.
difficile testing method by case year (2015 and 2018) and antibiotic treatment with the
potential moderation of clinical symptoms. The secondary correlational analysis included
patients admitted to a large suburban hospital with a positive test for C. difficile in 2015
and 2018 (N = 509). The relationship between the study predictor (case year), dependent
variable (antibiotic treatment), and moderator (symptom) was analyzed using binomial
logistic regression. Antibiotics showed a significant association with the case year (OR =
1.889) and no significant moderation with the addition of symptoms (OR = 1.303).
Health care providers may find these findings useful in standardizing treatment of C.
difficile through the implementation of additions to clinical algorithms, resulting in
positive social change. Increased education, and policy, through antibiotic-resistant
organism reduction, increased antimicrobial stewardship, and increased patient safety,
may have social implications.
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Section 1: Foundation of the Study and Literature Review
Clostridium difficile (C. difficile) is a spore-forming bacillus that is acquired
through orally ingesting the organism in the environment (Jump, 2013). The human
intestinal system protects most people from the organism colonizing (Lawley & Walker,
2013). Individuals who have had exposure to antibiotics such as Vancomycin are at risk
for C. difficile infection due to the changes in the microbiota in the intestines producing
symptomatic diarrhea (Isaac et al., 2017). The incidence of C. difficile in the United
States among patients at least 1 year of age was 130 per 100,000 or 15,512 cases in 2017
(Centers for Disease Control and Prevention [CDC], 2018). More than 50% (7,973) were
hospital-associated due to a positive test at least 4 days after admission to a health care
facility (CDC, 2019c, 2019d, 2020). The method used to identify C. difficile includes
different testing methods with the result guiding, in part, the patient’s course of treatment
(McDonald et al., 2018). Diagnostic stewardship is critical to the management,
identification, and appropriate treatment of C. difficile infection (Rock et al., 2018).
Background
Nucleic Acid Amplification Test
The nucleic acid amplification test (NAAT) is a sensitive and rapid test used to
determine the presence or absence of C. difficile in a stool sample (Truong et al., 2017).
The NAAT alone cannot distinguish between toxin negative and toxin positive C. difficile
(Truong et al., 2017). The guidelines for testing indicate that NAAT is sufficient for
diagnosis, but only in the presence of symptoms such as three or more liquid stools
within 24 hours or fever or an increase in serum creatinine (McDonald et al., 2018). The
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NAAT is not appropriate if other reasons for diarrhea have not been ruled out, such as the
use of laxatives or recent colon surgery (McDonald et al., 2018). The use of the NAAT
preliminarily identifies the possibility of C. difficile as one cause of diarrhea. However, it
does not provide enough clinical evidence because the confirmatory toxin is not able to
be identified with the NAAT (Quest Diagnostics, 2017).
Two-Step Testing
The two-step testing method was developed to identify stool specimens that were
toxin negative and required further testing to rule out potential causes for diarrhea other
than C. difficile (McDonald et al., 2018; Truong et al., 2017). The two-step method
includes an antigen (glutamate dehydrogenase [GDH]) test and a toxin test to identify the
presence of toxigenic C. difficile (Quest Diagnostics, 2017). If both tests are positive,
then the sample is considered positive for toxigenic C. difficile, and the physician should
treat accordingly (Quest Diagnostics, 2017). If the GDH is positive and the toxin is
negative, then a tiebreaker (NAAT) must be completed to confirm the result (Quest
Diagnostics, 2017). The result of the tiebreaker is used for treatment and determines the
most effective patient treatment strategy (Quest Diagnostics, 2017) . If the GDH and
toxin are negative, then the result is negative (Quest Diagnostics, 2017). The result used
for treatment and reporting is the final answer from either the NAAT or the toxin from
the two-step method.
Reasons for Change
The reasons for the change from a two-step algorithm to a single NAAT are
twofold. First is the consideration of turnaround time for receiving results. The result of a
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NAAT is available in less than an hour, while the two-step takes longer due to the
increased number of steps involved to obtain accurate results (Quest Diagnostics, 2017).
The other consideration is that the sensitivity is slightly less with the two-step versus the
NAAT. The change from a single NAAT to the two-step is not due to concerns related to
the capabilities of the testing procedures, but rather to the need to identify toxin-negative
samples for discerning appropriate treatment methods. The NAAT cannot classify toxin
status but can identify the presence or absence of C. difficile (Quest Diagnostics, 2017).
The only scientific evidence-based method to isolate the presence of toxin is to use a
toxin assay (Theiss, Balla, Ross, Francis, & Wojewoda, C.T, 2018)
Treatment Methods
Treatment of C. difficile depends on the level of the disease present and the status
of a recurrent or initial episode of C. difficile (McDonald et al., 2018). Patients without
symptoms of C. difficile, such as increased diarrhea (more than three episodes in 24
hours), increase in white blood cells, fever, abdominal pain, or ileus, should not be
treated (McDonald et al., 2018). Testing results should not be used without the clinical
collaboration of symptomology (McDonald et al., 2018). If the patient’s clinical
symptoms (with or without testing confirmation) are suspicious for C. difficile, then the
patient should be started on an antibiotic (McDonald et al., 2018). The regimen should
include vancomycin or fidaxomicin unless both are unavailable; then metronidazole is
suitable for the first episode of nonsevere C. difficile (McDonald et al., 2018). Patients
with recurrent C. difficile should be started immediately on vancomycin or fidaxomicin,
and patients with fulminant C. difficile regardless of the number of episodes should be
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started on vancomycin (McDonald et al., 2018). The inappropriate use of antibiotics for
C. difficile is simultaneously related to current accepted clinical testing and treatment
practices, and a lack of knowledge regarding patient outcomes over the long run when
antibiotics are prescribed unnecessarily to treat a suspected diagnosis of C. difficile.
Problem Statement
Antibiotic resistance, recurrent C. difficile, and prolonged hospitalization are
potential outcomes for patients identified with C. difficile in the hospital (CDC, 2019b);
Rock et al., 2018). Patients with a positive C. difficile test result without clinical
symptomology are at risk for inappropriate administration of antibiotics (Rock et al.,
2018). The Centers for Medicare and Medicaid Services instituted a requirement in 2013
for all acute care facilities to report all laboratory-identified C. difficile to assist in
holding administrators accountable through financial incentives for C. difficile infection
avoidance (Medicare Program Hospital Inpatient Prospective Payment Systems for Acute
Care Hospitals, 2017). Although patients are identified with a positive result of C.
difficile, physicians are strongly encouraged to confirm the infectious status through toxin
confirmation along with the presence of symptoms before prescribing treatment
(Ooijevaar et al., 2018).
One reason for the inappropriate treatment of C. difficile is the misclassification
of the presence of nontoxigenic C. difficile as an indication of infection (Ooijevaar et al.,
2018). The identification of C. difficile using the NAAT from both symptomatic and
asymptomatic patients is similar (Truong et al., 2017). A testing algorithm, including
both the NAAT and toxin confirmation testing, is another useful option for health care
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facilities to consider when identifying and attempting to distinguish between C. difficile
infection and colonization to guide appropriate treatment decisions (Truong et al., 2017).
Research is clear about the potential for the different testing methods to identify the
presence of toxigenic C. difficile and the reason for using each type based on the needs of
each facility (Ooijevaar et al., 2018). Many facilities have moved to the NAAT from a
cost perspective resulting in faster available results with standard guidelines for antibiotic
treatment (Amado, Bekker, Moshgriz, Keiser, & Siegel, 2016). However, the effect of a
change from a single NAAT to a two-step algorithmic testing method with a moderating
effect of patient symptomology upon antibiotic treatment is not well defined based on
available literature.
Purpose of the Study
The purpose of this study was to examine the effect of changing from the NAAT
to a two-step algorithm for the identification of C. difficile and the resultant prescribed
treatment for hospitalized patients with a modifying presence of symptoms. A
quantitative approach was used to address the gap regarding the relationship between the
testing year (2015 and 2018), antibiotic prescribing (yes or no), and recognized patient
symptomology (yes or no). The secondary de-identified patient data set, which included
the testing year, results, and antibiotics prescribed, was examined for differences. The
study was unique because it addressed moving from a specific testing method (NAAT)
conducted during 2015 to a two-step method that included toxin identification during
2018 (see Ooijevaar et al., 2018) along with the prescribing patterns, test results, and
recognized symptomology cues (see McDonald et al., 2018).
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Research Questions and Hypotheses
RQ1: Is there a statistically significant association between the testing period
(2015 and 2018) and antibiotic treatment (yes or no)?
Ho1: There is not a statistically significant association between the testing period
(2015 and 2018) and antibiotic treatment (yes or no).
Ha1: There is a statistically significant association between the testing period
(2015 and 2018) and antibiotic treatment (yes or no).
RQ2: Does the presence of a recognized symptom (yes or no) moderate the
relationship between the testing period (2015 and 2018) and antibiotic treatment (yes or
no)?
Ho2: The presence of a recognized symptom does not moderate the relationship
between the testing period (2015 and 2018) and antibiotic treatment (yes or no).
Ha2: The presence of a recognized symptom moderates the relationship between
the testing period (2015 and 2018) and antibiotic treatment (yes or no).
Theoretical Framework
The framework applicable to this study was the symbolic interaction theory (see
Goffman, 1967; Rose, 1962). The social interaction between the actor (physician) and the
world (the hospital) is the primary focus that guides the interaction or treatment of the
patient (see Goffman, 1967). The theory contains the following assumptions: (a) Humans
interact in both physical and symbolic environments, (b) a person’s response to a
symbolic communication is ascribed from learned behavior or meaning from others, and
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(c) a person’s experience is used to assign meaning to the behavior of others (see
Goffman, 1967; Rose, 1962).
C. difficile infection diagnosis requires a physician to complete a complex
decision-making process. The interactions or weighing by the physician of the particular
tool used for testing, the patient’s symptoms, and the need to treat are interrelated (see
Bobenchik, 2019). The physician’s decision to prescribe treatment is related to the
outcome of the testing and the accepted behavior through symbolic interactions among
physician peers within the facility. The present study focused on the interaction of the
testing method and the physician’s decision to treat. The research questions were related
to the theory in examining whether an association of symptoms is present as indicated
when using NAAT alone when testing for C. difficile to determine the need for treatment.
Nature of the Study
The nature of the study was quantitative with a correlational design including
secondary data from electronic medical records. The data set included records from
January 1, 2015, through December 31, 2015, and January 1, 2018, through December
31, 2018, from a large suburban health care facility with over 500 beds. All patients who
tested for C. difficile at the acute care facility with a positive result were included in the
analysis. The patient population under study included all ages and service status such as
intensive care or medical ward. The predictor variable was the case year (2015 or 2018).
The dependent variable was the treatment being prescribed (yes or no). The mediator
variable was whether a recognized symptom of C. difficile was present (yes or no).
Binary logistic regression was used for both research questions to determine association.
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Significance
According to the World Health Organization (2020), “patient safety is the absence
of preventable harm to a patient during the process of health care and reduction of risk of
unnecessary harm associated with health care to an acceptable minimum” (Patient safety
section, para. 1). Health-care-associated C. difficile harmed almost 224,000 hospitalized
patients in 2017 (CDC, 2019b). Correct identification of the disease is necessary to
ensure proper treatment (Bobenchik, 2019). The emergence of antibiotic-resistant C.
difficile is on the rise (CDC, 2018). The outcome of this study may increase awareness
and knowledge surrounding the appropriateness of treatment based on the two-step
testing results versus the treatments currently prescribed for NAAT results. Knowledge
regarding appropriate treatment requires precise results to determine the difference
between colonization and infection (Bobenchik, 2019). Testing methods and treatment
guidelines have been addressed in multiple research outcomes and scientific societal
guidelines (Bobenchik, 2019; Cho, Pardi, & Khanna., 2020; Crowell et al., 2017;
McDonald et al., 2018). However, the effect of a change from the NAAT to two-step
testing methods on prescribing patterns is not apparent (Ooijevaar et al., 2018; Truong et
al., 2017). The original contribution of this research was in two areas. First was the
review of following a counterintuitive path that requires two steps versus one step.
Second was the contribution to the physicians with documentation to identify patterns of
prescribing behavior among the population.
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Positive Social Impact
The identification of how prescribing patterns changed or did not change after the
implementation of two-step testing was one way to inform professional practice and to
identify appropriate or inappropriate antibiotic use. Inappropriate antibiotic use leads to
infections with antibiotic-resistant organisms, such as vancomycin-resistant enterococcus
(Isaac et al., 2017). One potential social outcome of the study was to increase awareness
among health care providers regarding the effect of treatment for C. difficile clinical
practice and the resultant impact on the antibiotic resistance problem that is prevalent in
the United States (see Colman, Krockow, Chattoe-Brown, & Tarrant, 2019; McCullough,
Rathbone, Parekh, Hoffmann, & Del Mar, 2015). If inappropriate antibiotic use is
identified, hospital administrations and medical staff may review the results to determine
better treatment algorithms.
The physicians who practice at the study facility are part of the same primary
group servicing multiple other facilities in the region. Sharing the clinical outcomes data
from this study with local physicians, local hospital infectious disease departments, and
local hospital administrators may improve testing and treatment outcomes within the
local community. Also, there is a possibility that the results may be generalized to other
populations, and that antibiotic-resistant cases may be minimized.
The identification and correction of inappropriately prescribed antibiotics may
positively affect patients, administrators, and providers. The benefits of decreasing the
overuse and misuse of antibiotics can positively affect everyone, including patients and
providers. For instance, patients who have nonmultidrug infections are less costly than
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patients who have multidrug-resistant infections (Chen & Fu, 2018). One of the primary
causes of C. difficile infection is the use of antibiotics; therefore, by reducing
inappropriate antibiotic use regardless of the prescription reason, the overall burden of C.
difficile may be reduced. In 2019, there were more than 2.8 million antibiotic-resistant
infections worldwide (CDC, 2019a).
Finally, C. difficile was responsible for 14,000 deaths and more than 200,000
infections in 2019, making the organism one of the top priorities for prevention and
control (CDC, 2019a). The ability to treat appropriately requires specific knowledge for
identifying the disease under scrutiny (CDC, 2019c). The contribution of this doctoral
project may be a local change in identifying the patterns of application or prescribing of
antibiotic use for C. difficile, which may lead to a decrease in antibiotic use. The decrease
in antibiotic use may lead to a reduction in multidrug-resistant organisms that expose
staff and patients to an increased risk of infection (CDC, 2019c).
Literature Search Strategy
The doctoral project included a search for relevant literature from multiple
databases. The search included CINAHL, Medline, PsycInfo, ScienceDirect, ProQuest,
and Embase databases for peer-reviewed scholarly journal articles published during or
after 2017. The initial search terms of c-diff or Clostridium difficile or C diff or c diff or c.
diff or CDI and test or testing and symptoms or signs or characteristics or presentation or
symptomatology resulted in 625 nonduplicative results. The search results were narrowed
using the search terms toxic or toxicity or toxigenic or toxin, which resulted in 593
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nonduplicative results. A final narrowing was conducted to include articles that met
specific inclusion criteria.
The inclusion criteria for the literature review included (a) relevance to the health
care industry, (b) English language articles, (c) relevance to C. difficile testing or
treatment, and (d) relevance to antibiotic use. Seminal works from as early as 1962
related to the symbolic interaction theory were included in the study. Also, the literature
review included six books and multiple internet-based subject-matter expert sources such
as the CDC. The final literature review included 104 articles.
Literature Review
Unnecessary antibiotic use contributes to the increased prevalence of diarrheal
episodes with longer episodic time frames and increased subsequent complications (Cho,
et al., 2020). Patients with C. difficile are more likely to have taken third-generation
cephalosporins for 3 or more days than those who do not have C. difficile (Lee et al.,
2019). The cause of C. difficile is unknown. However, the recognition of the symptoms
that leads to testing has been well researched (Hematyar et al., 2020; Truong et al., 2017).
Symptoms
Symptoms of C. difficile include diarrhea with abdominal cramps, fever,
increased serum creatinine, and increased white blood cell count in any combination
(McDonald et al., 2018; Rock et al., 2018). Confirmation of the symptoms, along with a
positive C. difficile test, is critical to the management of C. difficile (Cho et al., 2020;
Crowell et al., 2017; Ooijevaar et al., 2018). The definition endorsed by health care
facilities for diarrhea is three or more episodes of liquid stool that takes the shape of the
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container, and fever is a temperature above 100.4 Fahrenheit (CDC, 2020; Quest
Diagnostics, 2017). Abdominal cramps are subjective, and white blood cell count above
the patient’s normal levels are considered symptomatic (McDonald et al., 2018; Rock et
al., 2018). Although symptomatic carriers are more readily identified, consideration must
be given to asymptomatic carriers who may develop the disease with symptoms during
hospitalization (Kagan et al., 2017).
Testing
Testing methodologies include one or two tests to confirm the presence and
toxigenic status of the patient’s sample. The specimen quality (liquid only) is vital for
two reasons. If the NAAT is used, part of the process is to ensure only appropriate liquid
diarrheal specimens are tested because the test detects regardless of the sample type
(Goret et al., 2018). If an NAAT is used and the sample is not meeting diarrheal criteria,
then treatment may be instituted on asymptomatic patients (Goret et al., 2018). The issue
becomes whether the sample is toxigenic and whether the sample is indicative of a patient
with a current symptomatic disease (Kagan et al., 2017). One way to combat the carrier
status problem is to use a two-step approach that combines the NAAT with the GDH to
determine the status (Davis et al., 2019; Mawer et al., 2019). Implementation of a twostep process identifies those patients who have true toxigenic C. difficile and, if
symptomatic, require treatment (Davis et al., 2019).
Treatments and Outcomes
The outcome for patients with C. difficile is dependent on the severity of the
disease, the treatment, and associated risk factors including presence (Fisher & Halalau,
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2018; Gateau, Couturier, Coia, & Barbut, 2018; Novotný et al., 2018). The treatments per
the Infectious Disease Society of America guidelines are separated by the first episode,
first recurrence, or subsequent recurrences along with nonsevere, severe, or fulminant
(McDonald et al., 2018). The categorizations are standard among research experts (Cho
et al., 2020; Crowell et al., 2017). Patients who are undertreated for C. difficile are at
equal risk for mortality compared to those who are overtreated or appropriately treated
(Crowell et al., 2017). Length of stay at a facility is a risk factor for increased C. difficile
infection (Zhang et al., 2016). Length of stay remained static for inappropriately treated
patients in the study by Crowell et al. (2017). However, a significant length of stay
decrease was seen in appropriately treated patients (Crowell et al., 2017). Reductions in
hospital-onset laboratory identified C. difficile cases have been recognized with a twostep method (Block et al., 2018). However, an equal decrease has not been found in
antibiotic prescribing (Albert, Ross, Calfee, & Simon, 2018; Davis et al., 2019).
Although case counts have decreased, subsequent use of antibiotics has not decreased,
which has led to poor outcomes up to and including death (Patel et al., 2017).
Research indicated that testing methods have improved in efficiency and accuracy
(Amado et al., 2016; Bai et al., 2017; Block et al., 2018; Brukner et al., 2019; Chang et
al., 2019; Kamboj et al., 2018; Paitan et al., 2017). The agreement among scientists and
professional organizations is well documented regarding the clinical manifestations of
infection (McDonald et al., 2018; Ooijevaar et al., 2018; Reinink et al., 2017). Also,
treatment algorithms are documented based on the disease level (Ooijevaar et al., 2018;
Origüen et al., 2018; Simeunovic et al., 2017; Theiss et al., 2018; Truong et al., 2017). A
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gap exists in the research related to whether the existence of clinical symptoms moderates
the administration of antibiotic treatment based on a positive result between a two-step
method or an NAAT that may or may not have been appropriately collected.
Definitions
Dependent variable: Antibiotic treatment referred to the administration or
initiation of antibiotics used for C. difficile treatment. The antibiotics included
vancomycin, metronidazole, and fidaxomicin. The administration or continuation of any
of these antibiotics after testing counted as treatment (see Cho et al., 2020; Crowell et al.,
2017; Giancola, Williams, & Gentry, 2018; Ooijevaar et al., 2018).
GDH: Glutamate dehydrogenase, which is a species-specific test used for rapid
diagnostic testing for C. difficile (Quest Diagnostics, 2017). Most commonly used in
conjunction with toxin assays to determine presence and toxin status together (Quest
Diagnostics, 2017).
Moderating variable: Symptoms referred to temperature, white blood cell count,
or serum creatinine level. Temperature over 100.4, serum creatinine over 1.3 mg/dL, and
white blood cell count over 15 × 109/L counted as symptoms and were marked as yes (see
Bauer et al., 2012). Any other values in those lab values were counted as
nonsymptomatic or no. The lab value or vital sign must have been within 24 hours before
or after the test for C. difficile was conducted.
NAAT: The nucleic acid amplification test, which is a rapid diagnostic test that is
used to detect C. difficile toxin genes (Quest Diagnostics, 2017).
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Predictor variable: Testing period for January 1 to December 31, 2015, and
January 1 to December 31, 2018. All records during this time from patients with an
admission who were tested for C. difficile and a positive result were included.
Two-step method: The rapid diagnostic method used to detect toxigenic C.
difficile in stool specimens combining the toxin assay and clostridium-specific gene
detection with a second test performed if the results are mismatched (Johansson,
Karlsson, & Norén, 2016; Quest Diagnostics, 2017). The GDH and toxin testing result as
positive or negative for both the toxin and the C. difficile presence. If the GDH is
negative and the toxin is positive, then the result is positive. If the GDH is positive but
the toxin is negative, then another test is run as a tiebreaker (Quest Diagnostics, 2017).
Assumptions
I assumed that the collection of the specimens was done only if the patient
required testing. Second, I assumed that the nursing staff accurately documented the
temperatures. I also assumed that the knowledge regarding the testing varied by provider,
and testing was conducted only when appropriate based on the clinician’s understanding.
Finally, I assumed that the application of the serum creatinine or white blood cell changes
were attributed to the probable or possible C. difficile infection and not attributed to other
infectious processes, if present.
Scope and Limitations
The data set for the analysis was restricted to 2 years (2015 and 2018) in which a
positive test result was obtained. The reasons for limiting the scope were related to the
methodology of the project. The elimination of negative results focused the population on
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the cases related to the research question of positive case outcomes (see Creswell &
Creswell, 2017). Also, all extra variables were excluded from the data set, including only
those that were used in the analysis. Restriction of the antibiotics for treatment to only
three types (vancomycin, metradionazole, and fidaxomicin) ensured that only antibiotics
associated with treatment for C. difficile were included. In other words, the elimination of
other antibiotics helped to lower the level of dilution of the results (see Creswell &
Creswell, 2017).
One limitation of the study may have been the implementation of a strict rejection
process for inappropriate specimens that were not in place at either time. Because the
study focused on one facility, a limitation was potentially present for generalizing the
results to other facilities without further research. Based on these restrictions and
limitations, the conclusions of the study cannot be generalized to all health care facilities
or all comparisons of testing methods.
Summary
C. difficile is a significant societal issue because over- or undertreatment of the
disease impacts the overall morbidity and mortality of the population. The difference in
testing methods was concerning due to the subsequent treatment based on the results. If
the results are not correlated with the symptoms, then the patient may be inappropriately
treated. The trends of hospital-onset C. difficile continue to decrease without the
alignment of reducing antibiotic use (CDC, 2019b, 2018). One gap in the research was
whether antibiotic treatment prescribed based on the case year via a positive test result
was modified by the presence of recognized symptoms. Recognizing differences in
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testing and the presence of symptoms may help with initiatives to mitigate inappropriate
antibiotic prescriptions, which endangers the public health.
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Section 2: Research Design and Data Collection
The de-identified patient data records were collected on December 3 and 4, 2019,
through the electronic medical record system as a special request from corporate clinical
analytics. The secondary medical record set included the predictor variable of the case
year, which also indicated the testing method as only one method was used during each
case year. The record also included the dependent variable of antibiotic treatment and the
moderating variable of symptoms present. The rationale for using the data was that the
information available through the patient data records would provide an adequate sample
that was representative of the population and would provide the necessary data points
necessary for answering the research questions.
Population
The target population for the study included all patients who tested positive for C.
difficile in 2015 or 2018 (N = 509).
Sample Size Determination
Although the sample size was determined based on tests conducted for C. difficile,
a power analysis was performed using G-Power software (see Faul, Erdfelder, Buchner,
and Lang., 2009). I assumed a two-tail test, an odds ratio of 2.25, an alpha of 0.05, and a
minimum statistical power of 0.95. A null hypothesis probability of the dependent
variable being equal to 1 if the independent variable was equal to 1 of 0.40 produced a
minimum sample size of 325. The accurate a priori power analysis included an alpha
level of .05 to reduce type I error, and power level of .95 to reduce type II error. The
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effect size of 60% inappropriately treating was calculated based on the average for over
or under treating (see Crowell et al., 2017).
The data were accessed by contacting the clinical analytics team via the clinical
services group director of infection prevention with the authority to request and share the
data. The information included the test being conducted with a positive result on any
patient for the case years of 2015 and 2018 and for the specified facility. The data were
sent in an Excel file from the clinical services group infection prevention director.
Method of Data Collection
The data were collected by the clinical analytics team based on a positive result
for C. difficile presence during calendar years 2015 and 2018. The data were extracted
from electronic medical records. The standard confidentiality agreement that is signed
each year by every staff member was maintained via the approval process for access to
the documents through the Clinical Analytics Group. Reliability evidence was considered
with the ability to reconstruct the data set and analysis (see Stewart & Hitchcock, 2016).
One internal validity consideration was that historical context might have
included other events that affected the outcomes during each case year. Another internal
validity concern was maturation due to the possibility of changing patient types and
prescribers during the different range of collections (see Stewart & Hitchcock, 2016).
External validity concerns included the generalizability of the outcomes to different
settings and treatment variations, which may be related to the timing of testing or results
(see Stewart & Hitchcock, 2016).
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Variables
The main variables used in the analysis were clinical symptoms, case year, and
antibiotic treatment. Each variable was introduced into the data analysis model as the
predictor, dependent, or moderating variable. Table 1 lists all relevant variables examined
in this analysis, followed by subsections describing the variables in detail.
Table 1
All Variable Definitions and Coding
Variable name

Type of
measurement

Definition

Use

Variable codes

Case year
Length of stay

Nominal
Ratio

Predictor
Demographic

2015 or 2018
0-635

Collect_location

Nominal

Year of test
Length of stay for
admission during
which the test was
performed
Location of test
collection

Demographic

Symptom

Nominal

Moderator

Abx_administered

Nominal

Dependent

Yes or no

Know_Exp_Abx

Nominal

Independent

Yes or no

Onset

Nominal

Presence of
temperature, WBC,
or serum creatinine
above the standard
threshold
At least one of the
c.diff antibiotics
prescribed or
continued after
testing.
Known exposure
to antibiotics
within 30 days
before testing
NHSN
categorization of
the organism onset

Adult ER=1;
adult inpatient=2;
adult outpatient=3;
pediatric ER=4;
pediatric
inpatient=5
Yes or no

Independent

Hospital onset=1;
community onset=2
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Predictor Variable
The predictor variable was the test case year. The case year was dependent on the
date of the C. difficile test. No calculation or modifications were made to this variable.
The case year 2015 corresponded to the two-step method fully implemented, and the case
year 2018 corresponded to the NAAT only.
Dependent Variable
The dependent variable antibiotic treatment was the administration of C. difficile
targeted antibiotics, including vancomycin, metronidazole, and fidaxomicin (see Cho et
al., 2020; Crowell et al., 2017; McDonald et al., 2018). Based on medication
administration records for each patient, the date and time of antibiotic administration
were documented. Any administration of the targeted antibiotics was coded as “yes” for
the dependent variable indicating that the patient received antibiotic therapy after testing
or that antibiotic therapy continued after testing if already started before testing. If no
targeted antibiotic was administered after testing, then the antibiotic administration
variable was coded as “no.”
Moderator
The moderator variable symptoms included temperature, serum creatinine, and
white blood cell count. The temperature threshold to indicate a clinical symptom was
greater than 100.4 Fahrenheit. The temperature of 100.5 or more was coded as “yes” for
symptoms. Serum creatinine level above 1.3 mg/dl was coded as “yes” for a clinical
symptom. Finally, white blood cell counts above 15 × 109/L were coded as “yes.” Fever,

22
liver abnormality, and leukocytosis (increased white blood cell count) are indicative of C.
difficile infection (Bauer et al., 2012; McDonald et al., 2018).
Demographic and Additional Variables
Other data points were available for descriptive analysis, including collect
locations to define the geographical location within the facility. Length of stay or the time
from admitting to the collection was used to define the onset of the case per National
Healthcare Safety Network criteria (see CDC, 2020). Community onset included cases
identified within the first 3 days of admission, and the rest were hospital-onset cases (see
CDC, 2020). The length of stay was a continuous variable. Finally, known exposure to
antibiotics within 30 days before the case identification indicated the significant risk for
the development of C. difficile infection (Lee et al., 2019).
Statistical Design
IBM SPSS Statistics Version 25 was used for the data analysis of this study. The
data set was downloaded in Excel and cleaned in IBM SPSS Statistics Version 25. The
file was provided in an Excel format containing 509 records. Each record was thoroughly
reviewed for missing data or inconsistencies. No data records had missing information.
Variables not needed in the analysis were removed from the data set.
Binary logistic regression was chosen for statistical analysis, including variables
from both research questions. Binary logistic regression assumptions were met with a
dichotomous dependent variable (antibiotic treatment), nominal independent variables
(case year and symptoms), and independence of observations (see Lund Research Ltd.,
2018). Frequency tables were included for descriptive analysis of additional variables
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(length of stay, known exposure to antibiotics, and onset). In the binary logistic
regression, the probability cut value of 0.5 was used to determine the appropriate
classification (see Lund Research Ltd., 2018). The Wald test was used to identify
variables that had a significant effect at or above a p value of 0.5.
Research Questions
RQ1: Is there a statistically significant association between the testing period
(2015 and 2018) and antibiotic treatment (yes or no)?
Ho1: There is not a statistically significant association between the testing period
(2015 and 2018) and antibiotic treatment (yes or no).
Ha1: There is a statistically significant association between the testing period
(2015 and 2018) and antibiotic treatment (yes or no).
RQ2: Does the presence of a recognized symptom (yes or no) moderate the
relationship between the testing period (2015 and 2018) and antibiotic treatment (yes or
no)?
Ho2: The presence of a recognized symptom does not moderate the relationship
between the testing period (2015 and 2018) and antibiotic treatment (yes or no).
Ha2: The presence of a recognized symptom moderates the relationship between
the testing period (2015 and 2018) and antibiotic treatment (yes or no).
Threats to Validity
Historical internal validity was addressed by confirming the process change dates
for the C. difficile testing processes and policies (see Stewart & Hitchcock, 2016). The
laboratory department and infection prevention department personnel who are
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responsible for changes to the C. difficile testing processes confirmed no other historical
changes occurred during the two study years. Although no changes occurred in the
process, the medical staff and patients were continuously changing. New staff learning
the processes can lead to errors. However, the same continuous education was given
throughout each case year. No correction for this issue was available.
External validity consideration for the timing of testing and resultant antibiotic
prescriptions must be considered for generalization because an inpatient facility has staff
24 hours a day to result and prescribe where other facilities may not (see Stewart &
Hitchcock, 2016). This leads to a generalizing issue based on the location where testing
takes place because the current project was set only for an inpatient acute care facility.
The findings may not be applicable to long-term care facilities or outpatient settings.
Ethical Considerations
A facility-based institutional review board application was completed and
approved before study implementation. Data access to the secondary data set required
permission via an email from the clinical services group infection prevention director,
who requested the data on my behalf. Confidentiality, honesty, and integrity in all data
gathering, storage, and use were consistently maintained even though the data set was a
secondary data set that did require primary subject contact. All data will be kept secured
via password protection for at least 5 years.
Summary
Section 2 included the details regarding the study methodology. The assessment
included the statistical testing plan for the case year predicting the antibiotic treatment.
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The influence of a C. difficile symptom presence was assessed. Also, the onset
categorization, collect location, and length of stay were included in the assessment.
Validity, reliability, and ethical considerations were reviewed. The study results are
presented in Section 3.

26
Section 3: Results and Findings
I examined the influence of symptoms indicative of C. difficile among two
different case years in which a different testing method was employed each year. The
antibiotic-prescribing behavior of the physician was the dependent or outcome variable.
The study addressed the relationship between testing period, antibiotic treatment, and
presence of symptoms indicative of C. difficile infection. This section includes the
quantitative analysis, results, and interpretation of the results.
Data Collection of Secondary Data Set
The data included in this study originated from electronic medical records from a
large suburban health care facility with over 500 beds. A single data set included the two
years selected for analysis, 2015 and 2018. Discrepancy concerns included possible
missing data values, incorrect reporting of values, or potential bias. Bias was minimized
through the inclusion of objective variables based on test results. No missing data values
were identified in the data set. The potential for incorrect reporting, although not
eliminated, was minimized because the methods for reporting the test results, symptoms,
and descriptive values are standardized throughout the hospital based on standard policy
and procedure. The data set review included quality and validity assurance with no issues
identified.
Descriptive Statistics
The demographic population included a total sample size of 509 patients with the
inclusion of both 2015 and 2018 cases. The G*Power analysis resulted in a minimum
sample size of 325 with odds ratio = 2.25, alpha = 0.05, power = 0.95, and
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implementation of a priori. Table 2 includes results of the analysis conducted for the
length of stay to obtain mean, median, standard error of deviation, minimum, and
maximum values. Table 3 includes the results of the analysis for frequency and test for
proportions as the remainder of the variables were categorical and discrete in nature. No
data values were excluded.
Table 2
Descriptive Analysis for Length of Stay
Case year

Mean

Median

2015
2018

22.31
19.37

11.00
10.00

Standard
error
2.675
2.414

Minimum

Maximum

0
0

635
201

Table 3
Descriptive Analysis for Categorical Variables
Variable
Collect location

Symptom
Abx_administered
Know_Exp_Abx
Onset

Category
Adult ER
Adult inpatient
Adult outpatient
Pediatric ER
Pediatric inpatient
Yes
Yes
Yes
Hospital onset
Community onset

Case Year 2015
Frequency
Percentage
23
6.6
276
79.8
0
0
11
3.2
36
10.4
190
54.9
287
82.9
212
61.3
151
43.6
195
56.4

Case Year 2018
Frequency
Percentage
17
10.4
123
75.5
12
7.4
7
4.3
4
2.5
109
66.9
147
90.2
124
76.1
80
49.1
83
50.9

Analysis of Hypothesis
Research Question 1
RQ1: Is there a statistically significant association between the testing period
(2015 and 2018) and antibiotic treatment (yes or no)?
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Ho1: There is not a statistically significant association between the testing period
(2015 and 2018) and antibiotic treatment (yes or no).
Ha1: There is a statistically significant association between the testing period
(2015 and 2018) and antibiotic treatment (yes or no).
Binomial logistic regression was performed to determine whether a relationship
existed between the testing period and antibiotic treatment. The logistic regression model
was statistically significant, χ2(1) = 4.91, p < .05. The model explained 1.7%
(Nagelkerke R2) of the variance in antibiotic treatment and correctly classified 85.3% of
cases. Sensitivity was 100%, and specificity was 0%. The predictor variable case year
was statistically significant and shown to contribute to the model with the year 2015 set
as the reference (see Table 4). Patients in the case year 2018 had 1.889 times higher odds
of having antibiotic treatment than patients in the case year 2015. The unstandardized
Beta weight for the predictor variable 2018: B = [0.636], Wald = [4.506], p = .034. In
2018, the odds ratio increased by 89% [Exp (B) = 1.889, 95% CI (1.050, 3.397)] for
antibiotic treatment.
Table 4
Binary Logistic Regression: Case Year
Variables

B

Wald

Exp(B)

Case year

.636

4.506

1.889

95% C.I for EXP(B)
Lower
Upper
1.050
3.397

Sig
.034
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Research Question 2
RQ2: Does the presence of a recognized symptom (yes or no) moderate the
relationship between the testing period (2015 and 2018) and antibiotic treatment (yes or
no)?
Ho2: The presence of a recognized symptom does not moderate the relationship
between the testing period (2015 and 2018) and antibiotic treatment (yes or no).
Ha2: The presence of a recognized symptom moderates the relationship between
the testing period (2015 and 2018) and antibiotic treatment (yes or no).
Binomial logistic regression was performed to determine whether the relationship
between the testing period and antibiotic treatment was moderated by the presence of
symptoms. The logistic regression model was statistically significant, χ2(2) = 5.998, p <
.05. The model explained 2.1% (Nagelkerke R2) of the variance in antibiotic treatment
and correctly classified 85.3% of cases. Sensitivity was 100%, and specificity was 0%.
The predictor variable case year was statistically significant (see Table 5) with “2015” set
as the reference, and was not statistically significant with “No” set as the reference.
Patients in the case year 2018 had 1.831 times higher odds of having antibiotic treatment
than patients in the case year 2015 with the symptom moderating at 1.303 higher odds
ratio. The adjusted unstandardized Beta weight for the predictor variable 2018: B =
[0.605], Wald = [4.032], p = .045. In 2018, the odds ratio increased by 83% [Exp (B) =
1.831, 95% CI (1.015, 3.304)] for antibiotic treatment when accounting for the Symptom
moderator (see Table 5).
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Table 5
Binary Logistic Regression: Case Year With Symptom Moderator Adjusted
Variables

B

Wald

Exp(B)

Case year
Symptom

.605
.265

4.032
1.093

1.831
1.303

95% C.I for EXP(B)
Lower
Upper
1.015
3.304
.793
2.140

Sig
.045
.296

Summary
Before statistical analysis, all variables were validated and recoded. Descriptive
summaries with frequency and percentage were completed for all categorical variables.
Binary logistic regression was conducted for the two research questions. The alternative
hypothesis was accepted with statistical significance for the case year and antibiotic
treatment association. Therefore, there was a significant association between the case
year and antibiotic treatment. However, for the second research question, the null
hypothesis was accepted because no statistically significant association between case year
and antibiotic treatment with the moderating effect of the symptom presence existed. The
key findings, social change implications, and application to professional practice are
presented in Section 4.
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Section 4: Application to Professional Practice and Implications for Social Change
The aim of the study was to determine whether an association exists between the
type of C. difficile testing based on case year and antibiotic treatment in a large hospital
population. The secondary aim was to determine whether the presence of known C.
difficile symptoms moderated the relationship between case year and antibiotic treatment.
Death related to C. difficile incidence in the United States equaled approximately 70 per
1,000 infections in 2019 (14,000 deaths / 200,000 infections) (CDC, 2019a). The study
findings indicated whether a significant relationship exists between testing type based on
case year, antibiotic treatment and presence of C. difficile symptoms.
Key Findings
Case Year and Antibiotic Treatment
The case year was aligned with the type of test that was conducted on the group.
The NAAT was conducted in 2015, and GDH with Toxin was conducted in 2018. The
total case counts decreased by 51%; there were 346 cases in 2015 and 169 cases in 2018.
The decrease in testing from NAAT to GDH with Toxin is congruent with the literature
related to the efficiency of turnaround time (see Davis et al., 2019). The antibiotic
treatment percentage decreased by 8% from 90% in 2015 to 82% in 2018. The
combination of a large decrease in case counts with minimal decrease in antibiotic
treatment is congruent with current literature (see Albert et al., 2018; Davis et al., 2019).
The odds ratio of antibiotic treatment for C. difficile was 1.889 times higher in 2018
compared to 2015. The results increase the discipline clarity that GDH with Toxin testing
compared with NAAT was associated with higher antibiotic treatment odds.
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Case Year, Antibiotic Treatment, and Symptoms
The presence of at least one clinical symptom (white blood cell count increase,
fever, or serum creatinine increase) increased by 12% from 2015 (54.9%) to 2018
(66.9%). The increase indicates that the physicians may have been focusing more on the
agreed-upon criteria for testing, as evidenced in the literature (see Bauer et al., 2012;
McDonald et al., 2018). The addition of a moderator of clinical symptoms to the
relationship of case year and antibiotic treatment did not result in a statistically
significant association. The odds of the existence of the moderator (symptoms) with
antibiotic treatment was 30%. However, the addition of the moderator had only a 6%
change in odds for the case year and antibiotic treatment relationship with a resultant
83% higher odds of antibiotic treatment in 2018 compared to 2015. Therefore, the
presence of one or more symptoms known to be clinically relevant did not affect the
testing type and antibiotic treatment relationship.
Known Exposure to Antibiotics and Length of Stay
Two risks of developing C. difficile infection are known exposure to antibiotics
and length of stay in a facility (Lee et al., 2019; Zhang et al., 2016). The length of stay for
patients with positive C. difficile results in 2015 averaged 22.31 days and decreased to
19.37 days in 2018. The mean length of stay was at the top of the acceptable average
range for C. difficile infection and slightly under in 2018 (Zhang et al., 2016). Crowell et
al. (2017) suggested that one possible reason for the decrease may be that the antibiotic
treatment may have been appropriately applied. Patients taking third-generation
cephalosporins within 3 days before the positive test increased by approximately 15%
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from 2015 (61.3%) to 2018 (76.1%). Both case years of C. difficile infections showed
rates of previous exposure to antibiotics above 50%, which aligns with the research (Lee
et al., 2019).
Collect Location and Onset
The collect location was included as a demographic variable to address validity
concerns (see Stewart & Hitchcock, 2016). The collect location includes the general age
of the patient (pediatric versus adult) and inpatient or outpatient. The highest number of
samples collected in 2015 equaled 79.8% in an adult inpatient location and decreased by
4.3% in 2018. Pediatric inpatient specimens were second highest in 2015 with 10.4% and
2.5% in 2018. The total pediatric location samples equaled 13.6% in 2015 and half the
amount in 2018 at 6.7%. The total adult location samples were higher by 8% in 2018
(93.3%) compared to 2015 (86.4%). Combined outpatient or ER samples were double the
amount in 2018 (22.1%) compared to 2015 (9.8%). Finally, overall inpatient samples
showed a difference of 27.7% between 2015 (90.2%) and 2018 (77.9%).
The collection location is one of the criteria used to determine the onset category
of community-onset or hospital-onset. The hospital-onset rate of C. difficile infections in
the United States in 2017 was approximately 50% (CDC, 2019a, 2019b, 2020). The
hospital-onset rate in 2015 was 6.4% below the 2017 U.S. rate and was less than 1%
below the rate in 2018, indicating that the hospital rates are in line with the existing
literature (CDC, 2019a, 2019b, 2020). Facility administrators are financially incentivized
to have the lowest possible count of hospital-onset cases, and the percentage is moving in
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the wrong direction (Medicare Program Hospital Inpatient Prospective Payment Systems
for Acute Care Hospitals, 2017).
Alignment With the Theoretical Framework
The symbolic interaction theory refers to patient treatment as a result of
interactions between the physician (actor) and the hospital (world; Goffman, 1967). The
interactions between the physician, patient, and test findings initiate the decision-making
process as part of symbolic interaction theory (Bobenchik, 2019; Goffman, 1967; Rose,
1962). Physicians require ample knowledge regarding the application of test results,
clinical manifestation of illness, and appropriate treatment options that come from
multiple different interactions (CDC, 2019c). The physician considers the presence of
symptoms, test results, and antibiotic treatment options while weighing the potential of
over- or undertreating, which may lead to outcomes that cause harm or even death
(Crowell et al., 2017; Patel et al., 2017).
Limitations of the Study
The generalizability of the data was a limitation. The data were limited to a single
acute care facility with more than 500 beds in a suburban location. Another limitation
related to the location was the availability of services such as physician call, pharmacy
interaction, and size of the physician group. The differences in size, services, and type of
facility limited the generalizability of the data (see Stewart & Hitchcock, 2016). The
results are not generalizable to different size facilities or types (e.g., rehabilitation, longterm care facilities, or outpatient settings). The validity and reliability of data were
reviewed for accuracy before use.
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Recommendations
This study focused on the moderating effect of recognized symptoms on the
relationship of a change from NAAT to GDH/Toxin testing and antibiotic treatments.
The study findings indicated that the presence of symptoms did not significantly affect
the treatment being applied. Research exists related to appropriate treatment of C. difficile
based on the level of disease severity (McDonald et al., 2018). Further study of the
choices of antibiotic treatment based on the level of severity of illness with the identified
change in the testing method should be conducted. The additional research will provide
the opportunity to explore the association between testing methods, antibiotic treatment,
and severity of illness. An investigation into different facility sizes and types may help to
expand the generalizability of the current findings. Facilities of similar size and type may
apply the epidemiological findings from this study.
Implications for Professional Practice and Social Change
The study finding that symptoms did not moderate the antibiotic treatment
prescribing patterns indicates a potential antimicrobial stewardship concern. The potential
for increased severity in illness or antibiotic-resistant organisms stems from inappropriate
antibiotic use (Isaac et al., 2016). Successful treatment of C. difficile infection requires
multiple interactions (communicative, symbolic, physical) between the physician, patient,
and other medical staff leading to learned behavioral outcomes in the form of diagnosis
and treatment led by the physician (Bobenchik, 2019; Goffman, 1967; Rose, 1962).
One professional practice recommendation is to include the severity of illness
with documented symptoms as criteria for antibiotic therapy. The physician group has the
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potential to agree upon an approved treatment algorithm. The treatment algorithm also
addresses the community level. Many of the physicians work in multiple facilities, which
allows for the physician’s experience to spread the policy through interactions.
Organizationally, continued appropriate testing with the presence of clinical symptoms,
as found in the current study, supports the financial incentives by lowering the hospitalonset cases (see Medicare Program Hospital Inpatient Prospective Payment Systems for
Acute Care Hospitals, 2017). Finally, the societal impact is in the potential reduction in
global antibiotic-resistant organisms, C. difficile infection, and C. difficile death in the
United States (see CDC, 2019c; Colman et al., 2019; Isaac et al., 2017; McCullough et
al., 2015).
Conclusion
An examination of the association between testing method (case year), antibiotic
treatment post testing, and the presence of symptoms indicated that the presence of
symptoms (or lack of symptoms) did not change the relationship between testing method
and treatment for C. difficile positive patients. C. difficile has the potential for mortality if
not identified correctly and not treated in a timely or appropriate manner. Overtreatment
and undertreatment of C. difficile are crucial for physicians to monitor. The addition of an
improved algorithm with clinical symptoms and severity of illness defined may help
physicians protect patients from unintended harm. The implementation of the improved
algorithm and policy across the organization for the medical staff and clinical staff may
promote improved quality, patient outcomes, and overall health management.
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